pcn poster

Posters

Predictors of relapse in patients with schizophrenia and schizoaffective disorders in real-world data from a large health system

Despite a relatively low prevalence, schizophrenia is one of the top 15 causes of disability worldwide and among the most expensive mental disorders to treat. Relapse, commonly associated...

Kimberly Laubmeier , PhD;

10/26/2023

Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotics: A Survey of US Psychiatric Clinicians (Results from the DECIDE Survey)

Clinician perspectives on the use of long-acting injectable antipsychotics (LAIs) for the treatment of schizophrenia are central to understanding real-world barriers to LAI use. In this s...

Rolf T. Hansen , PhD;

10/26/2023

Premature Ejaculation, And The Phycological Impact Of Majority Of Female Sexual Dysfunction

We aim to investigate the elevated occurrence of Female Orgasmic Disorder (FOD) within our patient population, attributable to male sexual dysfunction (MSD) in their partners. Through a c...

Milo Obas , BS, EMT;

10/26/2023

Population Pharmacokinetics for Switching From Oral or Long-Acting Injectable Risperidone to RYKINDO® (Risperidone) for Extended-Release Injectable Suspension, a Novel Long-Acting Injectable, in Patients With Schizophrenia

In adult patients with schizophrenia, switching from RISPERDAL CONSTA® (RC) to RYKINDO® requires administration of the first RYKINDO injection 4-5 weeks after the last RC injection. For p...

Ying Dong , MD, PhD;

10/26/2023

Practice Patterns in Schizophrenia Diagnosis and Management: Identifying Gaps in Clinician Knowledge

Clinicians are challenged to diagnose, assess, and treat patients with schizophrenia. This CME based survey assessed current practice gaps among US based psychiatrists related to the diag...

Natalie Guevara , DVM, MPH;

10/26/2023

Precision Medicine and Target-Controlled Infusions Significantly Improves the Efficacy of Ketamine Therapy for Treatment-Resistant Depression

Precision Medicine and Target-Controlled Infusions (TCI) represent a novel methodology to enhance the effectiveness and durability of ketamine infusion therapy for treatment-resistant dep...

Gerald Grass ;

10/26/2023

Pharmacokinetics and Safety of RYKINDO® (Risperidone) for Extended-Release Injectable Suspension, a Novel Long-Acting Injectable Risperidone, in Patients With Schizophrenia and/or Schizoaffective Disorder

This randomized, open-label, relative bioavailability study comparatively evaluated the pharmacokinetics and safety of RYKINDO®, a novel long-acting risperidone administered biweekly (Q2W...

Ying Dong , MD, PhD;

10/26/2023

Physician Assistants/Associates Burnout and Intention to Leave Principal Clinical Position: A National Cross-Sectional Analysis

We undertook a national study to evaluate and quantify burnout levels among the PA workforce. The study’s findings highlight that approximately a third of PAs experience at least one symp...

Mirela Bruza-Augatis , MS, PA-C;

10/26/2023

Physician Perspective on Idiopathic Hypersomnia: Awareness, Diagnosis, and Impact on Patients

This online survey assessed US physicians’ familiarity with idiopathic hypersomnia and understanding of the diagnostic process and impact on patients’ lives. Most physicians agreed idiopa...

Marisa Whalen , PharmD;

10/26/2023

Pharmaceutical Pipeline of BI 1358894: Clinical Evidence for an Emerging Drug for the Treatment of Mental Health Conditions

Dysregulated emotional processing and overwhelming negative emotions are core symptoms of disorders such as posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) and ar...

Talal Al Habbab , PharmD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products